Yubo International Biotech Limited
YBGJ
$0.07
$0.019538.61%
OTC PK
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 0.00 | -- | -- | 3.50K | 22.30K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 0.00 | -- | -- | 3.50K | 22.30K |
| Cost of Revenue | -4.30K | 88.30K | 127.90K | 800.00 | 4.20K |
| Gross Profit | 4.30K | -88.30K | -127.90K | 2.70K | 18.10K |
| SG&A Expenses | 284.40K | 395.80K | 287.10K | 280.20K | 362.60K |
| Depreciation & Amortization | 42.40K | 49.60K | 44.80K | 46.50K | 115.10K |
| Other Operating Expenses | 30.50K | 87.40K | 138.50K | 85.30K | 57.70K |
| Total Operating Expenses | 353.00K | 621.10K | 598.30K | 412.90K | 539.60K |
| Operating Income | -353.00K | -621.10K | -598.30K | -409.40K | -517.30K |
| Income Before Tax | -352.90K | -621.10K | -598.30K | -409.50K | -517.40K |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -352.90K | -621.10K | -598.30K | -409.50K | -517.40K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 63.20K | 40.20K | 70.80K | 32.20K | -- |
| Net Income | -289.70K | -580.80K | -527.50K | -377.30K | -517.40K |
| EBIT | -353.00K | -621.10K | -598.30K | -409.40K | -517.30K |
| EBITDA | -310.60K | -572.70K | -552.30K | -362.90K | -402.30K |
| EPS Basic | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Normalized Basic EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS Diluted | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Normalized Diluted EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Average Basic Shares Outstanding | 119.82M | 119.82M | 119.82M | 119.82M | 119.82M |
| Average Diluted Shares Outstanding | 119.82M | 119.82M | 119.82M | 119.82M | 119.82M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |